SCHEMBL6588022

SCHEMBL6588022

COc1ccc([N+](=O)[O-])cc1C=CC(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
GLA P06280 1/20 0.57
PTGES O14684 1/20 0.55
TLR9 Q9NR96 1/20 0.54
TDP1 Q9NUW8 2/20 0.51
TTR P02766 1/20 0.51
LMNA P02545 1/20 0.50
NTSR1 P30989 1/20 0.50
KDM4E B2RXH2 1/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50
MAPK1 P28482 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CYP19A1 P11511 1/20 0.50
PTGS2 P35354 1/20 0.50
MAPT P10636 1/20 0.49
JUN P05412 1/20 0.49
NFKB1 P19838 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6588014 1.00 ALDH1A1 (0.57) ALDH1A1GLAPTGESTLR9TDP1
SCHEMBL7381862 0.91 ALDH1A1 (0.56) ALDH1A1GLAPTGESTLR9TTR
SCHEMBL7813598 0.89 ALDH1A1 (0.61) ALDH1A1GLAPTGESTDP1LMNA
SCHEMBL14931946 0.89 ALDH1A1 (0.61) ALDH1A1GLAPTGESTDP1LMNA
SCHEMBL7813596 0.89 ALDH1A1 (0.61) ALDH1A1GLAPTGESTDP1LMNA
SCHEMBL6981759 0.87 TLR9 (0.53) ALDH1A1GLATLR9TDP1LMNA
SCHEMBL6981756 0.87 TLR9 (0.53) ALDH1A1GLATLR9TDP1LMNA
SCHEMBL8393177 0.85 TLR9 (0.51) ALDH1A1GLATLR9TDP1TTR
SCHEMBL6591007 0.85 MAPT (0.54) ALDH1A1GLATLR9TDP1LMNA
SCHEMBL6591011 0.85 MAPT (0.54) ALDH1A1GLATLR9TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9937139-B2 β-substituted γ-amino acids and analogs as chemotherapeutic agents QUADRIGA BIOSCIENCES, INC. (US) 2018-04-10 US disclosed
US-20170246135-A1 BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS QUADRIGA BIOSCIENCES, INC. 2017-08-31 US disclosed
US-9682921-B2 β-substituted γ-amino acids and analogs as chemotherapeutic agents QUADRIGA BIOSCIENCES, INC. (US) 2017-06-20 US disclosed
EP-3102194-A1 BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS Quadriga Biosciences, Inc. (US) 2016-12-14 EP disclosed
US-20160289168-A1 BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS QUADRIGA BIOSCIENCES, INC. 2016-10-06 US disclosed
WO-2015117146-A1 BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS QUADRIGA BIOSCIENCES, INC. (US) 2015-08-06 WO disclosed
EP-1150977-B1 PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2004-08-25 EP disclosed
US-6699879-B1 OBESITY, DIABETES, SLEEP DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2004-03-02 US disclosed
US-4278748-A Absorbed hydrazide nucleating agents and photographic elements containing such agents EASTMAN KODAK COMPANY (US) 1981-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160289168-A1 BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS SLC3A2, SLC7A1, SLC43A1 ALDH1A1 632/4885GLA 2874/4885PTGES 3750/4885
US-20170246135-A1 BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS SLC3A2, SLC7A1, SLC43A1 ALDH1A1 632/4885GLA 2874/4885PTGES 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.